Viking Therapeutics Shares Surge 60% On Positive Obesity Drug Data
Product·2 articles across 2 outlets
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Viking Therapeutics' stock skyrocketed by 60% following the release of updated data from its obesity drug trials. The trial participants mostly kept their weight down after switching from a weight-loss drug to Viking's treatment, indicating promising results for the company's future in the obesity market.
In contrast, shares of competitors Roche and Novo Nordisk experienced declines, with Novo falling significantly. The positive data from Viking's trials has positioned the company favorably in a competitive landscape dominated by major players like Eli Lilly.
Viking TherapeuticsEli LillyNovo Nordisk
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“<figure><div><img”
biopharma dive — Viking shares surge on updated obesity drug data
SupportCorroborates it
“Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls.”
Yahoo Finance — Viking Therapeutics Skyrockets On Obesity Drug Data. Lilly Rises, But Novo Falls.